Are you Dr. Hartmann?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 57 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. Lynn Hartmann, MD is an oncologist in Rochester, Minnesota. She is currently licensed to practice medicine in Minnesota. She is a Professor at Mayo Medical School.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1986 - 1988
- University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1983 - 1986
- Northwestern University The Feinberg School of MedicineClass of 1983
Certifications & Licensure
- MN State Medical License 1986 - 2023
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Octreotide in Treating Patients With Cancer-Related Malignant Ascites Start of enrollment: 2005 Oct 01
Publications & Presentations
PubMed
- 7 citationsCoiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer.Sanjeev Kumar, Derek B. Oien, Ashwani Khurana, William A. Cliby, Lynn C. Hartmann
Frontiers in Oncology. 2019-10-01 - 35 citationsGenes associated with bowel metastases in ovarian cancerAndrea Mariani, Chen Wang, Ann L. Oberg, Shaun M. Riska, Michelle Torres
Gynecologic Oncology. 2019-09-01 - 10 citationsCellular fibroepithelial lesions of the breast: A long term follow up study.Saba Yasir, Aziza Nassar, Rafael E. Jimenez, Sarah M. Jenkins, Lynn C. Hartmann
Annals of Diagnostic Pathology. 2018-08-01
Press Mentions
- Tumor Heterogeneity for Differentiation Between Liver Tumors and Normal Liver Tissue in 18F-FDG PET/CTNovember 4th, 2020
- Preventive Surgery for Women at High Risk of Breast, Ovarian CancerFebruary 3rd, 2016
- Suspicious Breast Mass May Pose Greater Risk Than Previously ThoughtDecember 31st, 2014
- Join now to see all
Grant Support
- Mechanisms Of Immune Suppression In Ovarian CancerNational Cancer Institute2009–2011
- Mayo Clinic Spore In Ovarian CancerNational Cancer Institute2009–2011
- Administration CoreNational Cancer Institute2009–2011
- Risk Prediction For Breast Cancer: A Tissue-Based StrategyNational Cancer Institute2008–2011
- PAUL Calabresi Program In Clinical-Translational Research At Mayo ClinicNational Cancer Institute2006–2011
- Mayo Clinical Oncology Research Training ProgramNational Cancer Institute2004–2005
- Mayo Clinical Oncology Research Training ProgramNational Cancer Institute2001–2003
- Prophylctic Mastectomy In Hereditary Breast CancerNational Cancer Institute1999–2002
Professional Memberships
- Member